tetano
Editor, Senior Moderator
Clin Vaccine Immunol. 2011 May 25. [Epub ahead of print]
Cross-Protection of Chicken IgY Antibodies passively administered in mice against H5N1 and H1N1 Viruses.
Wallach MG, Webby RJ, Islam F, Walkden-Brown S, Emmoth E, Feinstein R, Gronvik KO.
Source
iThree Institute, University of Technology Sydney, Broadway, Australia.
Abstract
Influenza viruses remain a major threat to global health due to their ability to undergo change through antigenic drift and antigenic shift. We postulated that avian IgY antibodies represent a low-cost, effective and well-tolerated approach that can be easily scaled up to produce enormous quantities of protective antibodies. These IgY antibodies can be administered passively in humans (orally and intranasally), and can be used to quickly and safely help in the fight against an influenza pandemic. In this study, we raised IgY antibodies against H1N1, H3N2 and H5N1 influenza viruses. We demonstrated that using whole inactivated viruses alone and in combination to immunize hens, we were able to induce a high level of anti influenza virus IgY in the sera and eggs, which lasted for at least 2 months after two immunizations. Furthermore, we found that using in vitro assays to test for the ability of the IgY to inhibit haemagglutination (HI test) and virus infectivity (serum neutralisation test), IgYs inhibited the homologous as well as in some cases heterologous clades and strains of viruses. Using an in vivo mouse model system, we found IgY to H5N1 when administered intranasally 1 hour prior to infection, protected 100% of the mice against lethal challenge with H5N1. Of particular interest was the finding that IgY to H5N1 cross protected against A/Puerto Rico/8/34 (H1N1) both in vitro and in vivo. Based on our results, we conclude that anti influenza IgY can be used to help prevent influenza viral infection.
PMID:
21613458
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21613458
Cross-Protection of Chicken IgY Antibodies passively administered in mice against H5N1 and H1N1 Viruses.
Wallach MG, Webby RJ, Islam F, Walkden-Brown S, Emmoth E, Feinstein R, Gronvik KO.
Source
iThree Institute, University of Technology Sydney, Broadway, Australia.
Abstract
Influenza viruses remain a major threat to global health due to their ability to undergo change through antigenic drift and antigenic shift. We postulated that avian IgY antibodies represent a low-cost, effective and well-tolerated approach that can be easily scaled up to produce enormous quantities of protective antibodies. These IgY antibodies can be administered passively in humans (orally and intranasally), and can be used to quickly and safely help in the fight against an influenza pandemic. In this study, we raised IgY antibodies against H1N1, H3N2 and H5N1 influenza viruses. We demonstrated that using whole inactivated viruses alone and in combination to immunize hens, we were able to induce a high level of anti influenza virus IgY in the sera and eggs, which lasted for at least 2 months after two immunizations. Furthermore, we found that using in vitro assays to test for the ability of the IgY to inhibit haemagglutination (HI test) and virus infectivity (serum neutralisation test), IgYs inhibited the homologous as well as in some cases heterologous clades and strains of viruses. Using an in vivo mouse model system, we found IgY to H5N1 when administered intranasally 1 hour prior to infection, protected 100% of the mice against lethal challenge with H5N1. Of particular interest was the finding that IgY to H5N1 cross protected against A/Puerto Rico/8/34 (H1N1) both in vitro and in vivo. Based on our results, we conclude that anti influenza IgY can be used to help prevent influenza viral infection.
PMID:
21613458
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21613458